PT Merck Tbk (MERK.JK)
ValueMarkers Composite Index
89% below intrinsic value ($2)
PT Merck Tbk (MERK.JK) — VMCI valuation read
MERK.JK screens at VMCI 70/100, a 20-point gap above the Healthcare sector median (50). For a mid-cap PT Merck Tbk share, that placement says the multi-pillar composite is cheaper or higher quality than the typical peer on a like-for-like basis.
MERK.JK has logged no Form 4 insider activity over the trailing 30 days. The tape reads neither bullish nor bearish on insider conviction. The next signal sits with the 10-Q schedule and the analyst calendar.
**Investor frame.** Value: MERK.JK trades at 20.0x earnings, 11% above the Healthcare median of 18.0x, while EV/EBITDA prints 9.0x against 12.0x for the Healthcare group. Quality: ROIC of 16.0% sits 6.0pp above the Healthcare median (10.0%), the cleanest like-for-like comparison on capital efficiency. Risk: net debt to EBITDA of -1.9x leaves covenant headroom, which sets the rate-cycle exposure for PT Merck Tbk.
MERK.JK fell 1.0% over the trailing 7 days, with a -11.4% read on a 30-day basis.
PT Merck Tbk manufactures and sells pharmaceutical products in Indonesia. It operates through three segments: Biopharma, Consumer Health, and Others. It offers health care products in the areas of cardiovascular, metabolic, oncology, endocrinology, fertility, and neurodegenerative diseases, as well as general medicines. The company also engages in discovering, developing, manufacturing, and marketing pharmaceutical and biological prescription medicines to treat colorectal cancer, head and neck cancer, multiple sclerosis, infertility, growth hormone disorders, and diabetes, as well as thyroid disorders comprising hyperthyroidism and hypothyroidism. In addition, it leases and manages properties. The company was formerly known as PT Merck Indonesia Tbk and changed its name to PT Merck Tbk in June 2002. The company was founded in 1970 and is headquartered in East Jakarta, Indonesia. PT Merck Tbk is a subsidiary of Merck Holding GmbH.
Related Stocks in Healthcare
Top peers ranked by VM Score. Compare valuation, quality, and risk metrics across the sector.
- 7079.T - WDB coco Co., Ltd.
- 340570.KQ - T&L Co., Ltd.
- CSWYF - China Shineway Pharmaceutical Group Limited
- CSWYF - China Shineway Pharmaceutical Group Limited
- 7634.T - Hoshi Iryo-Sanki Co., Ltd.
- 7792.T - Colan Totte.Co.,Ltd.
- SPRINT.ST - Sprint Bioscience AB (publ)
- 043150.KQ - Value Added Technology Co., Ltd.